In the meantime, CMS (Centers for Medicare & Medicaid Services) created two demonstration programs: Medicare GLP-1 Bridge (July 2026 to December 2027): A short-term program providing Medicare Part D beneficiaries access to select FDA-approved GLP-1 medications for obesity at a $50 monthly copay
It is not an FDA-approved finished product, the FDA does not review it for safety, effectiveness, or quality before marketing, and it is not a generic version of any approved brand
, , , ,
Products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease
References Dong XX, Wang Y, Qin ZH
Healthcare professionals should work with patients to find the best course of treatment for them. Speaking in a personal capacity, Claire Davies, a diabetes and endocrinology specialist pharmacist at Gateshead Health NHS Foundation Trust, told The Pharmaceutical Journal : It is incredibly saddening that NHS and manufacturer supply chains have not been robust enough to prevent a large-scale shortage of a key medication for long-term condition management
